## Management of Acute Hepatitis B ### Clinical Context Acute hepatitis B in immunocompetent adults typically resolves spontaneously without antiviral intervention. The majority (>95%) of immunocompetent adults who acquire acute HBV infection will clear the virus and develop lifelong immunity. ### Treatment Approach **Key Point:** Acute hepatitis B in immunocompetent patients does NOT require antiviral therapy; supportive care is the standard of care. Antiviral agents (nucleos(t)ide analogues or interferon) are reserved for: - Fulminant hepatic failure - Immunocompromised patients - Severe acute hepatitis with prolonged INR or encephalopathy ### Why Antivirals Are Not First-Line in Uncomplicated Acute HBV | Scenario | Management | |----------|-------------| | Acute HBV, immunocompetent, no complications | Supportive care, monitor LFTs | | Acute HBV + fulminant failure | Consider lamivudine or entecavir | | Acute HBV + immunosuppression | Antiviral therapy indicated | | Chronic HBV (>6 months) | Antiviral therapy per guidelines | **High-Yield:** The distinction between acute and chronic hepatitis B is critical. Acute infection in immunocompetent hosts resolves spontaneously; chronic infection (HBsAg persistence >6 months) requires antiviral therapy based on HBeAg status, HBV DNA level, and ALT. ### Supportive Care Measures - Rest and nutritional support - Monitor for signs of hepatic decompensation (INR, bilirubin, encephalopathy) - Avoid hepatotoxic drugs and alcohol - Serial monitoring of LFTs and coagulation profile **Clinical Pearl:** If this patient had presented with fulminant hepatic failure (INR >1.5, encephalopathy, rapid bilirubin rise), lamivudine or entecavir would be indicated to reduce viral replication and allow hepatic regeneration.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.